Insulin aspart

门冬胰岛素

Report date: 2026/03/31 20:00:21

Base Information

Drug NameInsulin aspart
Drug Alias Name天冬胰岛素insulina aspartainsulinum aspartumUltra-fast-acting insulin aspartinsuline asparte +[15
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormone
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsCognitive DysfunctionPostoperative Cognitive ComplicationsHypercholesterolemia +[14
Global Approved IndicationsDiabetes Mellitus
Approved Indications in ChinaDiabetes Mellitus
Original Approved Country/TerritoryEU
Original Approved Date1999/09/07
Country/TerritoryCzechiaBelgiumCanada +[36
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovo Nordisk A/S
China Registration ClassN/A

Develop Information

Active IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus +[5
Inactive IndicationsCognitive DysfunctionPostoperative Cognitive ComplicationsHypercholesterolemia +[9

Other Information

ATC CodeA10AB05A10AD05